Mondego Bio
PrivateLast Round
Series A
Sep 18, 2025
Total Funding Raised
$23.74M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Mondego Bio is a biotechnology company developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors for immuno-oncological therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mondego Bio Comparables
Compare Mondego Bio with similar companies based on industry and business-model similarity.
Mondego Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 18, 2025 |
Mondego Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed | Series A |
| Biovance Capital Partners | Series A |
| Torrey Pines Investment LLC | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 8, 2025
Added Biovancecapital, a startup VC, as a customer.
- Oct 8, 2025
Added OrbiMed, a healthcare investment firm, as a customer.
Mondego Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mondego Bio's valuation, stock price, and market status.